Harvard Bioscience, Inc.

Harvard Bioscience, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. Harvard Bioscience, Inc. is a mediocre stock to choose.
Log in to see more information.
Harvard Bioscience, Inc. develops, manufactures, and markets broad range of specialized products, pr...
HBIO Fundamental Data by TradingView

News

Allspring Global Investments Holdings LLC Acquires New Stake in Harvard Bioscience, Inc. (NASDAQ:HBIO)
Allspring Global Investments Holdings LLC Acquires New Stake in Harvard Bioscience, Inc. (NASDAQ:HBIO)

Ticker Report Allspring Global Investments Holdings LLC acquired a new position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO - Free Report) in the second quarter, according to the company in its most recent...\n more…

Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference

Globe Newswire HOLLISTON, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial...\n more…

Harvard Bioscience (NASDAQ:HBIO shareholders incur further losses as stock declines 11% this week, taking three-year losses to 65%
Harvard Bioscience (NASDAQ:HBIO shareholders incur further losses as stock declines 11% this week, taking three-year losses to 65%

Simply Wall St Research Harvard Bioscience's (Nasdaq:HBIO) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more.\n more…

Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200-Day Moving Average of $3.70
Harvard Bioscience (NASDAQ:HBIO) Shares Pass Below 200-Day Moving Average of $3.70

Ticker Report Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO - Get Free Report) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $3.70 and traded as low...\n more…

Harvard Bioscience Announces Second Quarter 2024 Financial Results
Harvard Bioscience Announces Second Quarter 2024 Financial Results

Globe Newswire HOLLISTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the Company ) today announced financial results for the second quarter ended June 30, 2024. Jim Green...\n more…

Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt
Harvard Bioscience (NASDAQ:HBIO) Is Making Moderate Use Of Debt

Simply Wall St Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...\n more…